Three Peptides, Side by Side

The short version

This page lines up PT-141, Kisspeptin and Melanotan II on the dimensions that matter most: what each molecule is, what it has been studied for, how strong that evidence is, how it was given in studies, its regulatory standing, and its defining caution. The headline: all three interact with systems relevant to sexual desire or arousal, but through completely different mechanisms and from very different positions on the evidence spectrum. PT-141 has the strongest clinical data and an FDA-approved pharmaceutical form for a specific indication. Kisspeptin has compelling Phase 1/2 data in reproductive medicine but no approved form. Melanotan II has only early small-sample human data and documented serious safety cautions. None is presented here with a human dose.

The comparison matrix

Peptide class

All three belong to the melanocortin peptide family in some sense, but they diverge sharply in selectivity. PT-141 is selective for MC3R and MC4R — the central receptors — which is the result of deliberate chemical refinement away from Melanotan II's structure ^[16]. Melanotan II activates all five melanocortin receptor subtypes, including MC1R (pigmentation), MC5R (exocrine glands) and MC3R/MC4R (central effects). Kisspeptin is not a melanocortin peptide at all: it binds an entirely different receptor, KISS1R, and acts upstream of the melanocortin axis on the GnRH pulse generator ^[12]. The shared thread is that all three interact — via different routes — with systems relevant to sexual motivation.

Most-studied indication

PT-141's home territory is HSDD in premenopausal women, with two pivotal trials specifically in that group ^[3]. Early animal and human data also showed erectogenic activity in men, though no Phase 3 trial has been conducted in men ^[7]. Kisspeptin's most-studied applications are reproductive medicine — specifically LH stimulation, hypothalamic amenorrhea management, and IVF oocyte-maturation triggering as a safer alternative to hCG ^[10][11]. A parallel research thread links kisspeptin to sexual motivation at the neural level. Melanotan II's human data are mostly from early skin-pigmentation exploration and a small ED crossover trial; it never progressed to late-phase work for either indication ^[17].

Evidence base (model)

PT-141 has the strongest human evidence of the three: two double-blind, placebo-controlled Phase 3 RCTs in 1,267 women meeting both coprimary endpoints ^[3], plus a 52-week open-label extension ^[4]. Kisspeptin has a substantial Phase 1/2 record — 29 interventional trials identified in a 2025 systematic review — with well-characterized mechanistic and clinical data but no Phase 3 and no approval ^{[9][10][11][12]}. Melanotan II's controlled human data come from a single double-blind crossover in 10 men ^[17] and a handful of mechanistic animal studies ^[14]; the rest of the record is case reports, many documenting harms ^[13][15]. These are three compounds at very different stages of clinical development.

Administration studied

All three have been studied parenterally. PT-141's approved form is a subcutaneous injection; early mechanistic work used intravenous routes in animals ^[7]. Kisspeptin has been studied intravenously (infusion), subcutaneously, and most recently via intranasal spray ^[8][11][12]. Melanotan II was given subcutaneously in the primary human crossover study ^[17] and in the case reports documenting adverse events ^[13][15]. No oral form of any of the three has demonstrated validated clinical efficacy.

Regulatory / WADA status

PT-141 occupies the most complex regulatory position: bremelanotide is a genuine FDA-approved pharmaceutical for HSDD in premenopausal women ^[5], but research-grade material sold as PT-141 sits outside the pharmaceutical system. For uses beyond the approved indication — including use in men, postmenopausal women, or for performance — PT-141 falls under WADA's S0 (non-approved-substances) category ^[5]. Kisspeptin is not specifically listed by name on the WADA Prohibited List but as an unapproved peptide falls within regulated peptide hormone and metabolic modulator categories. Melanotan II is not approved anywhere and falls under WADA S0; multiple national regulators (FDA, TGA, MHRA, HPRA) have issued specific product warnings against melanotan-containing products ^[16].

Key caution

Each compound's defining caution differs. For PT-141, it is the narrow approval scope combined with common nausea (~40% over long-term use) and a transient blood-pressure increase that contraindicates use in hypertension or cardiovascular disease ^[4][5]. For Kisspeptin, it is tachyphylaxis: the receptor desensitizes under sustained or frequent activation, and the compound acts on the HPG axis in ways that are not characterized in all hormone-sensitive states ^[11]. For Melanotan II, it is the documented melanocyte-activation risk — new and changing moles, case-reported melanoma, renal infarction, and rhabdomyolysis — from a compound sold without quality oversight and without any regulatory approval ^[15]. Reading all three, the progression from Melanotan II to PT-141 illustrates how receptor selectivity shapes both the benefit and the risk profile.